摘要
目的 探究微小RNA-532-3p (miR-532-3p)、有丝裂原活化蛋白激酶(MAPK)在非小细胞肺癌患者靶向治疗耐药中的表达及其相关性。方法 选取2013年6月至2016年1月榆林市第一医院肿瘤诊疗中心收治的表皮生长因子受体(EGFR)基因突变非小细胞肺癌EGFR酪氨酸澈酶抑制剂(EGFR-TKIs)耐药患者30例作为耐药组,非耐药患者32例为非耐药组。血清中miR-532-3p、MAPK水平分别采用实时荧光定量PCR法、酶联免疫吸附法检测;χ^(2)检验分析血清miR-532-3p、MAPK表达水平与化疗客观有效率的关系;Kaplan-Meier法分析血清miR-532-3p、MAPK表达水平与5年生存期的关系;采用Cox回归模型分析影响非小细胞肺癌患者预后不良的因素。结果 耐药组患者的血清miR-532-3p水平为2.09±0.24,明显高于非耐药组的1.05±0.16,MAPK水平为(1.04±0.57) mg/L,明显低于非耐药组的(7.63±3.28) mg/L,差异均有统计学意义(P<0.05);化疗3个周期后,miR-532-3p低表达患者治疗有效率为62.50%,明显高于miR-532-3p高表达患者的33.33%,而MAPK低表达患者的治疗有效率为25.81%,明显低于MAPK高表达患者的70.97%,差异均有统计学意义(P<0.05);Kaplan-Meier分析结果显示,血清miR-532-3p低表达非小细胞肺癌患者5年累积生存率为84.4%,明显高于血清miR-532-3p高表达者的50.0%,差异有统计学意义(P<0.05);血清MAPK低表达非小细胞肺癌患者5年累积生存率为61.3%,略低于血清MAPK高表达者的74.2%,差异无统计学意义(P>0.05);经多因素Cox回归模型分析结果显示,miR-532-3p高表达、MAPK低表达是非小细胞肺癌患者发生靶向治疗耐药的独立危险因素(P<0.05)。结论 miR-532-3p、MAPK与非小细胞肺癌EGFR-TKIs耐药有关,检测两者表达可能为非小细胞肺癌的治疗提供新思路。
Objective To explore the expression and correlation of miR-532-3p and mitogen-activated protein kinase(MAPK) in targeted therapy resistance in patients with non-small cell lung cancer(NSCLC). Methods From June 2013 to January 2016, 30 NSCLC patients with epidermal growth factor receptor(EGFR) gene mutation and EGFR tyrosine kinase inhibitors(EGFR-TKIs) resistance admitted to the Cancer Diagnosis and Treatment Center, the First Hospital of Yulin were selected as the drug-resistant group, and 32 patients without resistance were selected as the non-drug-resistant group. Serum miR-532-3p and MAPK levels were detected by real-time fluorescence quantitative PCR and enzyme-linked immunosorbent assay, respectively. Chi-square test was used to analyze the relationship between serum miR-532-3p, MAPK expression levels and the objective effective rate of chemotherapy. Kaplan-Meier method was used to analyze the relationship between serum miR-532-3p, MAPK expression levels and 5-year survival.Cox regression model was used to analyze the factors affecting the poor prognosis of NSCLC patients. Results The serum mi R-532-3p level of the drug-resistant group was 2.09 ± 0.24, which was significantly higher than 1.05 ± 0.16 of the non-drug-resistant group, and the MAPK level was(1.04±0.57) mg/L, which was significantly lower than(7.63±3.28) mg/L of the non-drug-resistant group, with statistically significant differences(P<0.05). After three cycles of chemotherapy, the effective rate of patients with low expression of miR-532-3p was 62.50%, which was significantly higher than 33.33% of patients with high expression of miR-532-3p, while the effective rate of patients with low expression of MAPK was25.81%, which was significantly lower than 70.97% of patients with high expression of MAPK, with statistically significant differences(P<0.05). Kaplan-Meier analysis showed that the 5-year cumulative survival rate of patients with low serum mi R-532-3p expression was 84.4%, which was significantly higher than 50.0% of patients with high
作者
马彦娥
符号
郝光军
李婷
MA Yan-e;FU Hao;HAO Guang-jun;LI Ting(Cancer Diagnosis and Treatment Center,the First Hospital of Yulin,Yulin 719000,Shaanxi,CHINA)
出处
《海南医学》
CAS
2023年第1期6-10,共5页
Hainan Medical Journal
基金
陕西省榆林市科技计划项目(编号:【2019】185号-41)。
